Hepatitis C Facts - Vertex Pharma's Hep C Drug Could See $1.7B Sales
Vertex Pharma's Hep C Drug Could See $1.7B Sales
Forbes - Mar 14, 2006ThinkEquity Partners lowered the price target on Vertex Pharmaceuticals to $40 from $48 and said more data will be needed in order to determine the potential ...
Patients e-records facing legal hurdles
Kansas City Star, MO - Feb 28, 2006... The organization recently moved to 10603 Blue Ridge Blvd. There s no cure, and there s no vaccine for hep C, she said. ...
Human Genome Sciences Seen Partnering Hep C Drug In 2006
Forbes - Mar 16, 2006Piper Jaffray maintained an "outperform" rating on Human Genome Sciences and advised investors to buy on recent weakness in the stock. ...
Needle exchange made possible
Merritt Herald, Canada - 11 hours ago... "For me this is a ministry of humanity and a small way that we can be involved in the prevention of the spread of Hep C and HIV.". ...
Novartis Seen 'Saving Face' With Idenix Hep C Deal
Forbes - 13 hours ago... a research report Wednesday. "We think NM283 will make it to market and become a competitive hep C player.". Idenix shares fell 28 ...
